{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:36:24Z","timestamp":1785753384161,"version":"3.56.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40265-019-01204-y","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:15:02Z","timestamp":1571138102000},"page":"1785-1796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Stiripentol: A Review in Dravet Syndrome"],"prefix":"10.1007","volume":"79","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"1204_CR1","first-page":"89","volume-title":"Epileptic syndromes in infancy, childhood and adolescence","author":"C Dravet","year":"2005","unstructured":"Dravet C, Bureau M, Oguni H, et al. Severe myoclonic epilepsy in infancy: Dravet syndrome. In: Roger J, Bureau M, Dravet C, et al., editors. Epileptic syndromes in infancy, childhood and adolescence. Montrouge: John Libbey Eurotext Ltd.; 2005. p. 89\u2013113."},{"issue":"5","key":"1204_CR2","doi-asserted-by":"crossref","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","volume":"136","author":"YW Wu","year":"2015","unstructured":"Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310.","journal-title":"Pediatrics."},{"key":"1204_CR3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","volume":"44","author":"S Gataullina","year":"2017","unstructured":"Gataullina S, Dulac O. From genotype to phenotype in Dravet disease. Seizure. 2017;44:58\u201364.","journal-title":"Seizure."},{"issue":"Suppl 2","key":"1204_CR4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1528-1167.2011.03001.x","volume":"52","author":"P Genton","year":"2011","unstructured":"Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52(Suppl 2):44\u20139.","journal-title":"Epilepsia."},{"key":"1204_CR5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","volume":"128","author":"MS Cooper","year":"2016","unstructured":"Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43\u20137.","journal-title":"Epilepsy Res."},{"issue":"4","key":"1204_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","volume":"32","author":"KG Knupp","year":"2018","unstructured":"Knupp KG, Wirrell EC. Treatment strategies for Dravet syndrome. CNS Drugs. 2018;32(4):335\u201350.","journal-title":"CNS Drugs."},{"issue":"4","key":"1204_CR7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/mgg3.217","volume":"4","author":"T Dj\u00e9mi\u00e9","year":"2016","unstructured":"Dj\u00e9mi\u00e9 T, Weckhuysen S, Von Spiczak S, et al. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol Genet Genom Med. 2016;4(4):457\u201364.","journal-title":"Mol Genet Genom Med."},{"issue":"18\u201334","key":"1204_CR8","first-page":"e3","volume":"68","author":"EC Wirrell","year":"2017","unstructured":"Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68(18\u201334):e3.","journal-title":"Pediatr Neurol."},{"issue":"12","key":"1204_CR9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11940-018-0537-y","volume":"20","author":"J Ziobro","year":"2018","unstructured":"Ziobro J, Eschbach K, Sullivan JE, et al. Current treatment strategies and future treatment options for Dravet syndrome. Curr Treat Options Neurol. 2018;20(12):52 (1\u201315).","journal-title":"Curr Treat Options Neurol."},{"issue":"11","key":"1204_CR10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40263-012-0004-3","volume":"26","author":"GL Plosker","year":"2012","unstructured":"Plosker GL. Stiripentol: in severe myoclonic epilepsy of infancy (Dravet syndrome). CNS Drugs. 2012;26(11):993\u20131001.","journal-title":"CNS Drugs."},{"issue":"5","key":"1204_CR11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40263-017-0432-1","volume":"31","author":"KC Nickels","year":"2017","unstructured":"Nickels KC, Wirrell EC. Stiripentol in the management of epilepsy. CNS Drugs. 2017;31(5):405\u201316.","journal-title":"CNS Drugs."},{"issue":"4","key":"1204_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14737175.2019.1593142","volume":"19","author":"C Chiron","year":"2019","unstructured":"Chiron C. Stiripentol for the treatment of seizures associated with Dravet syndrome. Expert Rev Neurother. 2019;19(4):301\u201310.","journal-title":"Expert Rev Neurother."},{"key":"1204_CR13","unstructured":"European Medicines Agency. Stiripentol (Diacomit): EU summary of product characteristics. 2018. \nhttps:\/\/www.ema.europa.eu\/documents\/product-information\/diacomit-epar-product-information_en.pdf\n\n. Accessed 26 Feb 2019."},{"key":"1204_CR14","unstructured":"CRI. PrDiacomitTM (stiripentol capsules; powder for suspension): Canadian product monograph. 2012. \nhttps:\/\/pdf.hres.ca\/dpd_pm\/00022311.PDF\n\n. Accessed 26 Aug 2019."},{"key":"1204_CR15","unstructured":"Meiji Seika Pharma Co. Ltd. Stiripentol (Diacomit): Japanese prescribing information. 2013. \nhttp:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/1139011\n\n. Accessed 21 June 2019."},{"key":"1204_CR16","unstructured":"Biocodex Inc. Stiripentol (DIACOMIT): US prescribing Information. 2018. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206709s000,207223s000lbl.pdf\n\n. Accessed 26 Feb 2019."},{"issue":"9242","key":"1204_CR17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638\u201342.","journal-title":"Lancet."},{"issue":"Suppl. 8","key":"1204_CR18","first-page":"155","volume":"43","author":"R Guerrini","year":"2002","unstructured":"Guerrini R, Tonnelier S, d\u2019Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial [abstract no. P496]. Epilepsia. 2002;43(Suppl. 8):155.","journal-title":"Epilepsia."},{"key":"1204_CR19","unstructured":"Center for Drug Evaluation and Research. Application number: 206709Orig1s000 207223Orig1s000 Clin. Rev. 2018. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/206709Orig1s000,207223Orig1s000MedR.pdf\n\n. Accessed 6 June 2019."},{"issue":"2","key":"1204_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1528-1167.2007.01423.x","volume":"49","author":"B Kassai","year":"2008","unstructured":"Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343\u20138.","journal-title":"Epilepsia."},{"issue":"11","key":"1204_CR21","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","volume":"40","author":"J Perez","year":"1999","unstructured":"Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40(11):1618\u201326.","journal-title":"Epilepsia."},{"issue":"4","key":"1204_CR22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.eplepsyres.2014.02.008","volume":"108","author":"Y Inoue","year":"2014","unstructured":"Inoue Y, Ohtsuka Y. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108(4):725\u201331.","journal-title":"Epilepsy Res."},{"key":"1204_CR23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","volume":"113","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Ohtsuka Y. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90\u20137.","journal-title":"Epilepsy Res."},{"issue":"6","key":"1204_CR24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dmcn.13704","volume":"60","author":"KA Myers","year":"2018","unstructured":"Myers KA, Lightfoot P, Patil SG, et al. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60(6):574\u20138.","journal-title":"Dev Med Child Neurol."},{"issue":"7","key":"1204_CR25","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/j.1528-1167.2011.03107.x","volume":"52","author":"R Nabbout","year":"2011","unstructured":"Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54\u20137.","journal-title":"Epilepsia."},{"issue":"11","key":"1204_CR26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0929-693X(02)00090-8","volume":"9","author":"TN Thanh","year":"2002","unstructured":"Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet\u2019s syndrome). Arch Pediatr. 2002;9(11):1120\u20137.","journal-title":"Arch Pediatr."},{"issue":"9","key":"1204_CR27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/epi.14536","volume":"59","author":"C Chiron","year":"2018","unstructured":"Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59(9):1705\u201317.","journal-title":"Epilepsia."},{"issue":"11","key":"1204_CR28","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","volume":"50","author":"Y Inoue","year":"2009","unstructured":"Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362\u20138.","journal-title":"Epilepsia."},{"key":"1204_CR29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eplepsyres.2016.05.012","volume":"125","author":"P De Liso","year":"2016","unstructured":"De Liso P, Chemaly N, Laschet J, et al. Patients with Dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res. 2016;125:42\u20136.","journal-title":"Epilepsy Res."},{"issue":"9","key":"1204_CR30","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/epi.12303","volume":"54","author":"EC Wirrell","year":"2013","unstructured":"Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective US study. Epilepsia. 2013;54(9):1595\u2013604.","journal-title":"Epilepsia."},{"issue":"1","key":"1204_CR31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3988\/jcn.2018.14.1.22","volume":"14","author":"MJ Cho","year":"2018","unstructured":"Cho MJ, Kwon SS, Ko A, et al. Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations. J Clin Neurol. 2018;14(1):22\u20138.","journal-title":"J Clin Neurol."},{"issue":"1","key":"1204_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0883073818811538","volume":"34","author":"EP Yildiz","year":"2019","unstructured":"Yildiz EP, Ozkan MU, Uzunhan TA, et al. Efficacy of stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol. 2019;34(1):33\u20137.","journal-title":"J Child Neurol."},{"key":"1204_CR33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2014.10.014","volume":"109","author":"A Dressler","year":"2015","unstructured":"Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome\u2014comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81\u20139.","journal-title":"Epilepsy Res."},{"issue":"1","key":"1204_CR34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12611","volume":"135","author":"S Balestrini","year":"2017","unstructured":"Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135(1):73\u20139.","journal-title":"Acta Neurol Scand."},{"issue":"8","key":"1204_CR35","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14656566.2016.1161026","volume":"17","author":"C Chiron","year":"2016","unstructured":"Chiron C. Stiripentol and vigabatrin current roles in the treatment of epilepsy. Expert Opin Pharmacother. 2016;17(8):1091\u2013101.","journal-title":"Expert Opin Pharmacother."},{"key":"1204_CR36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.yebeh.2014.03.014","volume":"34","author":"A Strzelczyk","year":"2014","unstructured":"Strzelczyk A, Schubert-Bast S, Reese JP, et al. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86\u201391.","journal-title":"Epilepsy Behav."},{"issue":"7","key":"1204_CR37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dmcn.12709","volume":"57","author":"C Rosander","year":"2015","unstructured":"Rosander C, Hallbook T. Dravet syndrome in Sweden: a population-based study. Dev Med Child Neurol. 2015;57(7):628\u201333.","journal-title":"Dev Med Child Neurol."},{"key":"1204_CR38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yebeh.2014.12.028","volume":"44","author":"LM Aras","year":"2015","unstructured":"Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104\u20139.","journal-title":"Epilepsy Behav."},{"issue":"Pt A","key":"1204_CR39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.yebeh.2019.06.021","volume":"98","author":"S Schubert-Bast","year":"2019","unstructured":"Schubert-Bast S, Wolff M, Wiemer-Kruel A, et al. Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: a multicenter cohort study from Germany and review of literature. Epilepsy Behav. 2019;98(Pt A):88\u201395.","journal-title":"Epilepsy Behav."},{"issue":"8","key":"1204_CR40","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/epi.13057","volume":"56","author":"JM Wilmshurst","year":"2015","unstructured":"Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: task force report for the ILAE Commission of Pediatrics. Epilepsia. 2015;56(8):1185\u201397.","journal-title":"Epilepsia."},{"issue":"Pt 8","key":"1204_CR41","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/aws151","volume":"135","author":"A Brunklaus","year":"2012","unstructured":"Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(Pt 8):2329\u201336.","journal-title":"Brain."},{"key":"1204_CR42","unstructured":"European Medicines Agency. Cannabidiol (Epidyolex): EU summary of product characteristics. 2019.  \nhttps:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190919145790\/anx_145790_en.pdf\n\n. Accessed 3 Oct 2019."},{"key":"1204_CR43","unstructured":"Greenwich Biosciences Inc. EPIDIOLEX\u00ae (cannabidiol): US prescribing Information. 2018. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf\n\n. Accessed 26 Feb 2019."},{"issue":"Suppl 3","key":"1204_CR44","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1017\/cjn.2016.249","volume":"43","author":"EC Wirrell","year":"2016","unstructured":"Wirrell EC. Treatment of Dravet syndrome. Can J Neurol Sci. 2016;43(Suppl 3):S13\u20138.","journal-title":"Can J Neurol Sci."},{"issue":"3","key":"1204_CR45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejpn.2019.02.014","volume":"23","author":"A Strzelczyk","year":"2019","unstructured":"Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019;23(3):392\u2013403.","journal-title":"Eur J Paediatr Neurol."},{"issue":"2","key":"1204_CR46","first-page":"199","volume":"34","author":"M Poisson","year":"1984","unstructured":"Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant, stiripentol\u2014pharmacological profile and neurochemical study. Arzneimittel-Forschung\/Drug Research. 1984;34(2):199\u2013204.","journal-title":"Arzneimittel-Forschung\/Drug Research."},{"key":"1204_CR47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuropharm.2012.11.002","volume":"67","author":"DK Grosenbaugh","year":"2013","unstructured":"Grosenbaugh DK, Mott DD. Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model of benzodiazepine-refractory status epilepticus. Neuropharmacology. 2013;67:136\u201343.","journal-title":"Neuropharmacology."},{"issue":"6228","key":"1204_CR48","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.aaa1299","volume":"347","author":"N Sada","year":"2015","unstructured":"Sada N, Lee S, Katsu T, et al. Epilepsy treatment: targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347(6228):1362\u20137.","journal-title":"Science."},{"issue":"4","key":"1204_CR49","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","volume":"47","author":"PP Quilichini","year":"2006","unstructured":"Quilichini PP, Chiron C, Ben-Ari Y, et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA(A)-receptor channels. Epilepsia. 2006;47(4):704\u201316.","journal-title":"Epilepsia."},{"issue":"1","key":"1204_CR50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","volume":"56","author":"JL Fisher","year":"2009","unstructured":"Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56(1):190\u20137.","journal-title":"Neuropharmacology."},{"issue":"Suppl. 2","key":"1204_CR51","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1528-1167.2011.03008.x","volume":"52","author":"JL Fisher","year":"2011","unstructured":"Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011;52(Suppl. 2):76\u20138.","journal-title":"Epilepsia."},{"issue":"2","key":"1204_CR52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2010.12.037","volume":"654","author":"JL Fisher","year":"2011","unstructured":"Fisher JL. Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines. Eur J Pharmacol. 2011;654(2):160\u20135.","journal-title":"Eur J Pharmacol."},{"issue":"2","key":"1204_CR53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jnr.23688","volume":"94","author":"M Verleye","year":"2016","unstructured":"Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2016;94(2):179\u201389.","journal-title":"J Neurosci Res."},{"issue":"5","key":"1204_CR54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.eplepsyres.2014.03.009","volume":"108","author":"S Peigne","year":"2014","unstructured":"Peigne S, Rey E, Le Guern ME, et al. Reassessment of stiripentol pharmacokinetics in healthy adult volunteers. Epilepsy Res. 2014;108(5):909\u201316.","journal-title":"Epilepsy Res."},{"issue":"6","key":"1204_CR55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40262-017-0592-7","volume":"57","author":"S Peigne","year":"2018","unstructured":"Peigne S, Chhun S, Tod M, et al. Population pharmacokinetics of stiripentol in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy. Clin Pharmacokinet. 2018;57(6):739\u201348.","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"1204_CR56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","volume":"62","author":"A Tran","year":"1997","unstructured":"Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490\u2013504.","journal-title":"Clin Pharmacol Ther."},{"key":"1204_CR57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eplepsyres.2016.12.014","volume":"130","author":"T Jogamoto","year":"2017","unstructured":"Jogamoto T, Yamamoto Y, Fukuda M, et al. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res. 2017;130:7\u201312.","journal-title":"Epilepsy Res."},{"key":"1204_CR58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/FTD.0000000000000367","volume":"39","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto Y, Takahashi Y, Imai K, et al. Effect of CYP inducers\/inhibitors on topiramate concentration: clinical value of therapeutic drug monitoring. Ther Drug Monit. 2017;39:55\u201361.","journal-title":"Ther Drug Monit."},{"key":"1204_CR59","unstructured":"Ben-Menachem E, Gunning B, Cabrera CMA, et al. A phase 2 trial to explore the potential for a pharmacokinetic drug\u2013drug interaction with stiripentol when in combination with cannabidiol (CBD) in patients with epilepsy [poster 338]. In: International epilepsy congress, 2019."},{"key":"1204_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.665","author":"G Morrison","year":"2019","unstructured":"Morrison G, Crockett J, Blakey G, et al. A Phase 1, open-label, pharmacokinetic trial to investigate possible drug\u2013drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharm Drug Dev. 2019. \nhttps:\/\/doi.org\/10.1002\/cpdd.665\n\n.","journal-title":"Clin Pharm Drug Dev."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01204-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01204-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01204-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:26:08Z","timestamp":1602631568000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01204-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":60,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01204-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"15 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James Frampton is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}